Sign up to save your podcasts
Or
Share Abivax CEO Marc de Garidel discusses Obefazimod's phase 3 trial result in ulcerative colitis, and what is next for the company
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Abivax CEO Marc de Garidel discusses Obefazimod's phase 3 trial result in ulcerative colitis, and what is next for the company
He covers the mechanism of action, this week's efficacy and safety data, what it might mean for the maintenance trial that will read out in 2Q26, additional indications, IP, business development, and more.
View all episodes
By BiotechTV
5
44 ratings
He covers the mechanism of action, this week's efficacy and safety data, what it might mean for the maintenance trial that will read out in 2Q26, additional indications, IP, business development, and more.
More shows like BiotechTV - News
View all
Planet Money
30,635 Listeners
Odd Lots
1,867 Listeners
a16z Podcast
1,087 Listeners
The Readout Loud
325 Listeners
The Journal.
6,083 Listeners
Biotech 2050 Podcast
60 Listeners
All-In with Chamath, Jason, Sacks Friedberg
9,844 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
34 Listeners
Biotech Hangout
19 Listeners
ACQ2 by Acquired
260 Listeners
BG2Pod with Brad Gerstner and Bill Gurley
499 Listeners
The Studio at Kendall Square
0 Listeners
Off-Target Effects with Matt Gline
4 Listeners
Biotech CEO Sisterhood
2 Listeners
BioVenture VoiCes with Chris Garabedian
6 Listeners